Ocular Therapeutix™ adopts BSI’s CTMS software for its Ophthalmology clinical trials
BSI Life Sciences today announced biopharma Ocular Therapeutix (NASDAQ: OCUL) as its latest client to go live with its c…
BSI Life Sciences today announced biopharma Ocular Therapeutix (NASDAQ: OCUL) as its latest client to go live with its c…
B. Braun and REVA Medical hereby announce the strategic partnership for the distribution of Fantom® Encore - a bioresorb…
Ein ETH-Forschungsteam stellt mittels einem 3D-Druckverfahren einen neuartigen bioresorbierbaren Atemwegsstent her. Da…
Future Market Insights provides an in-depth analysis of the global coronary stents market in a new report titled “Corona…
Data presented during the TCT congress on BIOTRONIK’s Magmaris1 RMS provide further evidence on its continued safety and…
A new funding instrument is launched in German-Russian research cooperation. The Helmholtz Association and the Russian S…
In der deutsch-russischen Forschungszusammenarbeit startet ein neues Förderinstrument. Die Helmholtz-Gemeinschaft und d…
BIOTRONIK’s Magmaris resorbable scaffold offers a reduced risk of thrombus formation compared to a polymeric scaffold*.…
Twenty-four month data from the BIOSOLVE-II study reveal the long-term safety, efficacy and stability of BIOTRONIK’s Mag…
BIOTRONIK announced today that the Magmaris bioresorbable scaffold has received CE mark approval. The first clinically p…